Yes, the customer-friendly blood testing in India would be incredibly &quot;disruptive&quot; to American lab tests. Not only does the US have different costs and regulations but the medical industry is based on extracting money from insurance companies so every process is a bit occluded.<p>That said, Theranos is still on the hook because a business model innovation would probably not justify their valuation and PR compared to a tech innovation.